Wegovy (Semaglutide 2.4 mg) Vomiting: Diet Protocols That Help

How common is vomiting on Wegovy 2.4 mg?

In pooled Wegovy 2.4 mg injection trials, vomiting occurred in 24% of adults on Wegovy and 6% on placebo [1]. The safety set included 2,116 people on Wegovy and 1,261 on placebo for up to 68 weeks [1]. Vomiting led to permanent discontinuation in 1.2% of Wegovy-treated adults and 0% of placebo-treated adults [1]. Severe gastrointestinal reactions were reported in 4.1% of people on Wegovy injection and 0.9% on placebo [1].

What diet steps does the label support?

The label's diet instruction is general: Wegovy is used with a reduced-calorie diet and increased physical activity [1]. Semaglutide delays gastric emptying [1], but the Wegovy label does not give a specific meal size, fat gram limit, calorie target, or fluid target for vomiting [1].

The injection is given once weekly, on the same day each week, at any time of day, with or without meals [1]. Eating around injection time is not required [1].

What does the label say about dose steps?

Wegovy injection starts at 0.25 mg weekly for 4 weeks and increases every 4 weeks: 0.5 mg, 1 mg, 1.7 mg, then maintenance from week 17 [1]. Maintenance is 2.4 mg (recommended) or 1.7 mg [1]. The escalation schedule is intended to minimize gastrointestinal adverse reactions [1]. If a dose is not tolerated during escalation, the label says to consider delaying escalation for 4 weeks [1].

When is vomiting a warning sign?

The label lists acute pancreatitis as a warning. Persistent severe abdominal pain, sometimes radiating to the back, may or may not be accompanied by nausea or vomiting; if pancreatitis is suspected, the label says to discontinue Wegovy and start appropriate management [1].

The label also warns about acute kidney injury due to volume depletion and says to monitor renal function in patients reporting adverse reactions that could lead to volume depletion [1]. Wegovy is not recommended in patients with severe gastroparesis [1].